Hisayuki Yokoyama

ヨコヤマヒサユキ | Hisayuki Yokoyama

Affiliation and department：

Research field (1)： Hematology and oncology

Research theme for competitive and other funds (2)：

2021 - 2024 同種臍帯血移植後に生じる抗白血病NK細胞の解明とその生体外誘導法の検討
2004 - 2004 再生不良性貧血の分子標的治療に向けた基礎検討

Papers (104)：

Aki Sato, Nozomi Yusa, Hiroyuki Takamori, Eigo Shimizu, Kazuaki Yokoyama, Satoshi Ichikawa, Hisayuki Yokoyama, Yuki Kasahara, Kodai Enda, Fumiyoshi Fujishima, et al. Common progenitor origin for Rosai-Dorfman disease and clear cell sarcoma. The Journal of pathology. 2024
Satoshi Ichikawa, Hisayuki Yokoyama, Noriko Fukuhara, Ryo Ichinohasama, Hideo Harigae. Diffuse large B-cell lymphoma of the skull vault. International journal of hematology. 2024. 119. 3. 215-216
Kensuke Usuki, Shigeki Ohtake, Sumihisa Honda, Mitsuhiro Matsuda, Atsushi Wakita, Yuichiro Nawa, Ken Takase, Akio Maeda, Nobuo Sezaki, Hisayuki Yokoyama, et al. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). International journal of hematology. 2024. 119. 2. 130-145
Yuto Sasaki, Satoshi Ichikawa, Kazuki Sakurai, Hiroshi Nakamura, Kyoko Inokura, Koichi Onodera, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Hideo Harigae. [Multiple myeloma with IgH::MYC and multiple extramedullary lesions]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2024. 65. 3. 147-152
Kensuke Usuki, Shigeki Ohtake, Sumihisa Honda, Mitsuhiro Matsuda, Atsushi Wakita, Yuichiro Nawa, Ken Takase, Akio Maeda, Nobuo Sezaki, Hisayuki Yokoyama, et al. Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). International journal of hematology. 2024. 119. 1. 24-38

ｍore...

MISC (239)：

橋本和貴, 大西康, 福原規子, 横山寿行, 市川聡, 小野寺晃一, 猪倉恭子, 川尻昭寿, 中村嘉詞, 櫻井一貴, et al. 臍帯血移植後の深在性真菌感染症抗糸状菌活性を有する抗真菌薬の有効性. 日本血液学会学術集会. 2023. 85回. 72-72
渡邉樹也, 小野寺晃一, 鳴海善洋, 橋本和貴, 内堀雄介, 小松弘香, 竹中健人, 中村嘉詞, 櫻井一貴, 市川聡, et al. 進行胃癌に対するニボルマブ投与後に発症した後天性血小板減少性紫斑病の一例. 日本血液学会学術集会. 2023. 85回. 192-192
横山寿行, 鈴木千恵, 真山晃史, 小松弘香, 竹中健太, 鳴海善洋, 渡邉樹也, 中村嘉詞, 櫻井一貴, 橋本和貴, et al. 同種移植前微小残存病変がNPM1変異陽性急性骨髄性白血病の移植予後に及ぼす影響. 日本血液学会学術集会. 2023. 85回. 203-203
鳴海善洋, 市川聡, 福原則子, 小野寺晃一, 大西康, 横山寿行, 一迫玲, 張替秀郎. 初発時限局病変として発症し治療後に再発した節外性NK/T細胞リンパ腫の予後. 日本血液学会学術集会. 2023. 85回. 293-293
内堀雄介, 福原規子, 小松弘香, 竹中健太, 鳴海善洋, 渡邉樹也, 中村嘉詞, 櫻井一貴, 橋本和貴, 猪倉恭子, et al. 当院における再発難治性の濾胞性リンパ腫に対するCAR-T療法の後方視的検討. 日本血液学会学術集会. 2023. 85回. 412-412

ｍore...

Books (2)：

WHO血液腫瘍分類-WHO分類2017をうまく活用するために
医薬ジャーナル社 2018
WHO血液腫瘍分類-WHO分類2008をうまく活用するために
医薬ジャーナル社 2010

Lectures and oral presentations (7)：

Blockade of T Cell Anergy by Tyrosine Kinase Inhibitor, Sorafenib May Induce Exacerbation of Gvhd In Allogeneic Hematopoietic Stem Cell Transplantation.
(52nd ASH Annual Meeting 2010)
Adoptive Transfer of Natural Killer (NK) Cells to Prevent Gvhd and Enhance GVT Effects After Allogeneic Hematopoietic Cell Transplantation (HCT): The Timing of Donor NK Cell Infusions Critically Impacts Transplant Outcome.
(2009)
Adoptively-Infused NK Cells Maintain Their Antitumor Effects in Vivo in the Presence of CyclosporineA (CSA)
(American Society of Hematology 50th Annual Meeting 2008)
Cyclosporine a (CSA) Significantly Reduces the Cytotoxic Effects of in vitro Expanded NK Cells: Implications for Adoptive NK Cell Therapy in the Setting of Allogeneic Hematopoietic Stem Cell (HCT) Transplantation
(BMT Tandem meeting 2008)
Bortezomib Enhances the Antitumor Activity of Adoptively Infused Natural Killer Cells In Vivo: A Novel Approach To Override KIR-Mediated Inhibition of NK Cell Cytotoxicity.
(2007)

ｍore...

Professional career (1)：

MD, PhD (Tohoku University)

Association Membership(s) (5)：

American Society of Hematology , THE JAPAN SOCIETY OF TRANSFUSION MEDICINE AND CELL THERAPY , 日本造血細胞移植学会 , THE JAPANESE SOCIETY OF HEMATOLOGY , THE JAPANESE SOCIETY OF INTERNAL MEDICINE

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page